The revolutionary gene editing technology CRISPR-Cas is on the verge of widespread application in agriculture, promising easy access to dramatic crop improvements. Companies now licensing the technology face the challenge of regaining the public trust that was lost in the GM debate. Additional insecurity comes from the ongoing patent dispute between two renowned US institutions.
